{"id":24640,"date":"2024-06-02T23:56:00","date_gmt":"2024-06-02T15:56:00","guid":{"rendered":"https:\/\/www.granitefirm.com\/blog\/us\/?p=24640"},"modified":"2025-11-07T11:27:43","modified_gmt":"2025-11-07T03:27:43","slug":"mash-breakthrough","status":"publish","type":"post","link":"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/","title":{"rendered":"FDA approved first ever MASH drug"},"content":{"rendered":"\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #ffffff;color:#ffffff\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #ffffff;color:#ffffff\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Steatohepatitis_MASH\" >Steatohepatitis (MASH)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Introduction\" >Introduction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#How_many_patients_are_there\" >How many patients are there?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#How_big_is_the_market\" >How big is the market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#A_new_blue_ocean_for_pharma\" >A new blue ocean for pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Difficulties\" >Difficulties<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#FDA_just_approved_first_NASH_drug\" >FDA just approved first NASH drug<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Several_well-known_drugs\" >Several well-known drugs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#New_indications_for_weight_loss_drugs\" >New indications for weight loss drugs<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#survodutide_from_Zealand\" >survodutide from Zealand<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Novo_Nordisks_semaglutide\" >Novo Nordisk\u2019s semaglutide<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Eli_Lillys_Mounjaro\" >Eli Lilly&#8217;s Mounjaro<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Non-weight_loss_drugs\" >Non-weight loss drugs<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Akeros_Efruxifermin\" >Akero&#8217;s Efruxifermin<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Lanifibranor_by_Inventiva\" >Lanifibranor by Inventiva<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Denifanstat_by_Sagimet\" >Denifanstat by Sagimet<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Resmetirom_by_Madrigal\" >Resmetirom by Madrigal<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#The_leader\" >The leader<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Has_been_approved\" >Has been approved<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Vikings_VK2809\" >Viking&#8217;s VK2809<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/#Relative_articles\" >Relative articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Steatohepatitis_MASH\"><\/span>Steatohepatitis (MASH)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Introduction\"><\/span>Introduction<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/en.wikipedia.org\/wiki\/Metabolic_dysfunction%E2%80%93associated_steatotic_liver_disease\" target=\"_blank\" rel=\"noreferrer noopener\">Metabolic dysfunction-associated fatty liver disease (MASLD) is the name adopted in 2023 for the disease formerly known as non-alcoholic fatty liver disease (NAFLD)<\/a>. This condition is diagnosed when there is excessive accumulation of fat in the liver (hepatic steatosis) and at least one metabolic risk factor is present. The term MetALD is used when moderate alcohol consumption is also present and to distinguish it from alcoholic liver disease (ALD) when it is the sole cause of steatosis. <\/p>\n\n\n\n<p>The terms NAFL (non-alcoholic fatty liver) and MASH non-alcoholic steatohepatitis (formerly NASH, non-alcoholic steatohepatitis) have been used to describe varying degrees of severity, with the latter indicating the presence of further liver inflammation. NAFL is less dangerous than NASH and usually does not progress to NASH, but this progression may eventually lead to complications such as cirrhosis, liver cancer, liver failure, and cardiovascular disease. It is often caused by diet-related fat accumulation in the liver, leading to inflammation that may later lead to cirrhosis; some patients may even require organ transplants.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_many_patients_are_there\"><\/span>How many patients are there?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to estimates by Frost &amp; Sullivan, there are currently an estimated 115 million NASH hepatitis patients worldwide. In 2030, the number of NASH patients worldwide and in China will reach 486 million and 56 million respectively. The main users are in the United States, Western Europe and Japan. Professional studies show that 12% of Americans and 6% of Europeans have suffered from this disease.<\/p>\n\n\n\n<p>Madrigal projects that 1.5M Americans have been diagnosed with NASH, with obesity and diabetes among the factors driving the disease&#8217;s prevalence.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_big_is_the_market\"><\/span>How big is the market?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to Frost &amp; Sullivan&#8217;s forecast, the market capacity of NASH drugs will exceed US$10 billion by 2025, with a compound growth rate of 20.19% from 2016 to 2025.<\/p>\n\n\n\n<p>Research group GlobalData estimates that NASH will become a market worth more than $25 billion by 2026. Moreover, this market will grow by 45% every year starting from the introduction of prescriptions by big pharmaceutical companies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_new_blue_ocean_for_pharma\"><\/span>A new blue ocean for pharma<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The number of patients is huge, but treatment drugs are quite scarce. Such an attractive market has attracted the layout of pharmaceutical giants such as Gilead, Novartis, and Merck, but unfortunately they have all failed. There are currently hundreds of NASH drugs under development around the world, targeting nearly 20 targets such as THR-\u03b2, FGF21, PPAR and GLP-1.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Difficulties\"><\/span>Difficulties<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The reason why NASH treatment drugs are scarce is not only because of the complex pathogenesis of NASH, but also because of the strict clinical endpoint identification by the FDA: pathological evaluation by liver puncture is required, and imaging evaluation and hematological evaluation cannot be used as the primary endpoint for marketing approval.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_just_approved_first_NASH_drug\"><\/span>FDA just approved first NASH drug<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Among them, Madrigal\u2019s Resmetirom (will be mentioned later), which has undergone Phase III trials, was approved by the FDA on March 14, 2024, becoming the first new NASH hepatitis drug to be regulatory approved in history (see details below)). <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Several_well-known_drugs\"><\/span>Several well-known drugs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"New_indications_for_weight_loss_drugs\"><\/span>New indications for weight loss drugs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>There have been a number of weight loss drug fires that have caused the stock prices of manufacturers to soar, including Eli Lilly (ticker: LLY) and Novo Nordisk (ticker: NOVO), also from Denmark, which have become the European market capitalization due to the development of weight loss drugs Ozempic and Wegovy. The highest company. For this part, please refer to my previous posts for detailed discussions:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/07\/weight-loss-is-golden-goose\/\">Weight loss is the future golden goose of the drug market<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/11\/15\/eli-lilly-value-king\/\" target=\"_blank\" rel=\"noreferrer noopener\">Why Eli Lilly become global pharmaceutical market value king?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/29\/big-pharma-spin-offs\/\">Big pharma spin-offs, and advantages to invest them<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/09\/eli-lilly\/\">Eli Lilly, a big pharma with astonishing valuation<\/a>&#8220;<\/li>\n<\/ul>\n\n\n\n<p>The booming development of the weight-loss drug market has made a lot of money for many pharmaceutical companies. The following pharmaceutical companies have used the treatment of NASH hepatitis as a new indication for their new weight-loss drugs. Importantly, these weight loss drugs all use GLP-1.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"survodutide_from_Zealand\"><\/span>survodutide from Zealand<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Danish pharmaceutical company Zealand Pharm (ticker: ZLDPF) is not far behind. The company announced a trial result on February 26, 2024, which showed that one of its liver disease treatment drugs was effective, stimulating the company\u2019s stock price to rise on February 26, 2024. It soared 36% on the day.<\/p>\n\n\n\n<p>Zealand Pharma and German partner Boehringer Ingelheim (unlisted) stated in an announcement on February 26, 2024 that the phase II trial of the company&#8217;s survodutide drug showed that 83% of adult subjects the drug has shown positive results in the treatment of metabolic dysfunction-associated steatohepatitis (NASH).<\/p>\n\n\n\n<p>The company hopes to launch the drug in 2027 or 2028, depending on whether Phase 3 trial results are favorable. Analysts said the trial results showed a &#8220;clear victory&#8221; for the drug. Preliminary results show that survodutide was effective in treating NASH hepatitis at all doses used in the trial, and treatment with survodutide showed no unexpected safety or tolerability issues, including at the higher dose of 6.0 mg.<\/p>\n\n\n\n<p>The drug survodutide suppresses appetite by mimicking the gut hormone GLP-1 (glucagon-like peptide-1), like other injectable weight-loss drugs, but it also mimics another hormone called glucagon. of intestinal hormones. Survodutide also belongs to the GLP-1 (glucagon-like peptide-1) class of drugs, similar to Novo Nordisk\u2019s Wegovy.<\/p>\n\n\n\n<p>There are currently five Phase III clinical trials underway in overweight or obese people, and the drug has been designated as a fast track development drug by the U.S. Food and Drug Administration (FDA). The trial results show that the drug is safe even at the highest doses.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novo_Nordisks_semaglutide\"><\/span>Novo Nordisk\u2019s semaglutide<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Novo Nordisk is conducting a Phase 3 trial of semaglutide, the active ingredient in its Wegovy weight loss injection, against NASH hepatitis, with results expected to be announced in 2028.<\/p>\n\n\n\n<p>According to Novo Nordisk&#8217;s announcement, semaglutide showed positive results in the phase 2 clinical trial of NASH. Among the patients in the highest dose semaglutide treatment group, 66.7% of the patients&#8217; NASH symptoms were eliminated.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Eli_Lillys_Mounjaro\"><\/span>Eli Lilly&#8217;s Mounjaro<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Eli Lilly&#8217;s weight-loss drug Mounjaro, also known as Zepbound, is also testing its active ingredient in a Phase 2 trial for NASH hepatitis. The drug has a dual mechanism of action, based on two hormones: GLP-1 and GIP (gastric inhibitory peptide). Lilly is currently in the second phase of clinical trials and expects to complete the main study in the first half of 2024.<\/p>\n\n\n\n<p>The results of Mounjaro&#8217;s second phase trial showed that the rate of liver fibrosis no longer worsening at a dose of 0.4 mg could reach up to 59%.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Non-weight_loss_drugs\"><\/span>Non-weight loss drugs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akeros_Efruxifermin\"><\/span>Akero&#8217;s Efruxifermin<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>In terms of FGF21 analogues, Efruxifermin developed by Akero (ticker: AKRO) is ahead of the curve. It has taken the lead in launching the third phase of trials in December 2023 and is expected to be completed in April 2026. According to the Phase IIb study, both dosage groups of Efruxifermin achieved the primary endpoint and multiple secondary endpoints of improving liver fibrosis, and the liver biopsy data were impressive. The test results show that the proportion of liver fibrosis no longer worsening at the dose of 28 mg can reach up to 63%.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lanifibranor_by_Inventiva\"><\/span>Lanifibranor by Inventiva<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Inventiva&#8217;s (ticker: IVA) Lanifibranor is an oral PPAR agonist. Trial results show that a dose of 1.2 mg can prevent liver fibrosis from worsening by up to 49%. The Phase III study is expected to be completed in September 2025. If positive clinical data is successfully obtained, an application for accelerated approval from the FDA may be made in the first half of 2026.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Denifanstat_by_Sagimet\"><\/span>Denifanstat by Sagimet<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>On January 22, 2024, Sagimet (ticker: SGMT) announced that the Phase IIb study of Denifanstat in the treatment of NASH had achieved positive results, and its stock price soared 170%.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Resmetirom_by_Madrigal\"><\/span>Resmetirom by Madrigal<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_leader\"><\/span>The leader<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p>Resmetirom developed by Madrigal (ticker: MDGL) is a THR-\u03b2 inhibitor. In December 2022, Madrigal announced that its Phase III trial of Resmetirom in the treatment of NASH was successful.<\/p>\n\n\n\n<p>According to the results of the phase III trial, compared with the placebo group, 26% and 30% of patients who received 80 mg and 100 mg of Resmetirom for 52 weeks achieved remission of NASH symptoms, respectively.<\/p>\n\n\n\n<p>In December 2022, Madrigal&#8217;s stock price soared 268% the day after the clinical data of Resmetirom was released.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Has_been_approved\"><\/span>Has been approved<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p>The U.S. Food and Drug Administration (FDA) has approved Madrigal\u2019s resmetirom on March 14, 2024 as the first drug approved in the United States to treat non-alcoholic steatohepatitis (NASH) liver disease. Its approval marks medical history. a landmark decision.<\/p>\n\n\n\n<p>The once-daily oral thyroid hormone receptor (THR) agonist therapy, branded Rezdiffra, will be available in the United States with a price tag of US$47,000. According to FDA label information, the drug, called REZDIFFRA, will be indicated for adults with NASH and moderate to advanced liver fibrosis.<\/p>\n\n\n\n<p>With the announcement of this bullish news, Madrigal&#8217;s stock price surged by 24% immediately after the results.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vikings_VK2809\"><\/span>Viking&#8217;s VK2809<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Based on THR-\u03b2 agonists, Viking (ticker: VKTX) announced in May 2023 that the Phase II Voyage study of VK2809 in the treatment of NASH reached the primary endpoint (evaluating changes in liver fat content in patients at week 12) &#8211; Liver in the VK2809 group The proportion of patients whose fat content was reduced by at least 30% was as high as 84.9%. Data on liver puncture are expected to be announced in the first half of 2024.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"121\" height=\"118\" src=\"https:\/\/www.granitefirm.com\/blog\/us\/wp-content\/uploads\/sites\/2\/2024\/02\/NASH-1600x1200-1.jpg\" alt=\"MASH\" class=\"wp-image-24642\"\/><figcaption class=\"wp-element-caption\">credit: thelivertransplant.com<\/figcaption><\/figure>\n\n\n\n<p><strong><em>I am the author of the original text, the essence of this article was originally published in Smart Magz<\/em><\/strong><em><strong>ine, issue of May 2024 <\/strong><\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Relative_articles\"><\/span>Relative articles<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2025\/11\/06\/hca-healthcare\/\">How does HCA Healthcare make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2025\/10\/18\/chinese-biotech-deepseek\/\">Chinese biotech begins to show its DeepSeek moment<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2025\/09\/16\/akesos-beat-best-drug\/\">Akeso\u2019s lung cancer drug beat world best-selling drug, a biotech DeepSeek watershed<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/11\/02\/gene-editi-casgevy\/\">World\u2019s first gene editing therapy Casgevy finally approved<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/11\/17\/how-does-crispr-the-gene-editing-inventor-make-money\/\">How does CRISPR, the gene editing inventor, make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/02\/mash-breakthrough\/\" target=\"_blank\" rel=\"noreferrer noopener\">FDA approved first ever MASH drug<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/28\/gilead-aids-vaccine\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gilead, lord of antiviral drug, reveals world&#8217;s first AIDS vaccine<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2024\/06\/06\/viking\/\" target=\"_blank\" rel=\"noreferrer noopener\">Viking is developing two future star new drugs at the same time<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/07\/weight-loss-is-golden-goose\/\">Weight loss is the future golden goose of the drug market<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/12\/07\/alzheimer-progress\/\" target=\"_blank\" rel=\"noreferrer noopener\">Alzheimer, the only major disease yet to be conquered, current progress and related companies<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/11\/15\/eli-lilly-value-king\/\" target=\"_blank\" rel=\"noreferrer noopener\">Why Eli Lilly become global pharmaceutical market value king?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/29\/big-pharma-spin-offs\/\">Big pharma spin-offs, and advantages to invest them<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/08\/09\/eli-lilly\/\">Eli Lilly, a big pharma with astonishing valuation<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/06\/22\/pfizer-the-largest-pharma\/\">Pfizer, the world&#8217;s largest pharmaceutical company<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/03\/30\/novo-nordisks-new-diabetes-drug-semaglutide-and-incretin-found-to-have-surprising-weight-loss-effects\/\">Novo Nordisk&#8217;s new diabetes drug Semaglutide,Ozempic,Wegovy and Mounjaro found to have surprising weight-loss effects<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/11\/18\/prescription-leader-abbvie\/\">The next No. 1 pharmaceutical leader AbbVie<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/06\/24\/stable-dow-component-merck\/\">Stable Dow Component Merck, how does it make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/11\/06\/the-ex-largest-pharma-merck\/\" target=\"_blank\" rel=\"noreferrer noopener\">The ex-largest pharma Merck<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/07\/02\/abbott-laboratories\/\" target=\"_blank\" rel=\"noreferrer noopener\">Abbott, the world\u2019s most important medical device and nutritional food supplier, how does it make money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/05\/17\/roche\/\">Roche, the king of anti-cancer<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/09\/21\/how-johnson-johnson-make-money\/\" target=\"_blank\" rel=\"noreferrer noopener\">How the best AAA credit rating Johnson &amp; Johnson makes money?<\/a>&#8220;<\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2022\/04\/04\/intuitive-surgical\/\">How does dominated Intuitive Surgical make money?&#8221;<\/a><\/li>\n\n\n\n<li>&#8220;<a href=\"https:\/\/www.granitefirm.com\/blog\/us\/2023\/01\/16\/improvers-not-inventors\/\">Inventors are rarely successful, but improvers are successful and profitable<\/a>&#8220;<\/li>\n<\/ul>\n\n\n\n<p><em><strong>Disclaimer<\/strong><\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>The content of this site is the author\u2019s personal opinions and is for reference only. I am not responsible for the correctness, opinions, and immediacy of the content and information of the article. Readers must make their own judgments.<\/em><\/li>\n\n\n\n<li><em>I shall not be liable for any damages or other legal liabilities for the direct or indirect losses caused by the readers&#8217; direct or indirect reliance on and reference to the information on this site, or all the responsibilities arising therefrom, as a result of any investment behavior.<\/em><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Madrigal\u2019s Resmetirom was approved by the FDA on March 14, 2024, becoming the first new NASH hepatitis drug to be regulatory approved in history<\/p>\n","protected":false},"author":1,"featured_media":24642,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[115,114,120],"tags":[1229,1236,1227,752,1237,753,1228,1231,1230],"class_list":["post-24640","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","category-new-technology","category-pharmaceutical","tag-akro","tag-ions","tag-iva","tag-lly","tag-mdgl","tag-novo","tag-sgmt","tag-vktx","tag-zldpf"],"_links":{"self":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts\/24640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/comments?post=24640"}],"version-history":[{"count":50,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts\/24640\/revisions"}],"predecessor-version":[{"id":39810,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/posts\/24640\/revisions\/39810"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/media\/24642"}],"wp:attachment":[{"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/media?parent=24640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/categories?post=24640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.granitefirm.com\/blog\/us\/wp-json\/wp\/v2\/tags?post=24640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}